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Identification of somatic rearrangements in cancer
genomes has accelerated through analysis of high-
throughput sequencing data. However, characteriza-
tion of complex structural alterations and their
underlying mechanisms remains inadequate. Here,
applying an algorithm to predict structural variations
from short reads, we report a comprehensive catalog
of somatic structural variations and the mechanisms
generating them, using high-coverage whole-
genome sequencing data from 140 patients across
ten tumor types. We characterize the relative contri-
butions of different types of rearrangements and
their mutational mechanisms, find that 20% of the
somatic deletions are complex deletions formed by
replication errors, and describe the differences
between the mutational mechanisms in somatic
and germline alterations. Importantly, we provide
detailed reconstructions of the events responsible
for loss of CDKN2A/B and gain of EGFR in glioblas-
toma, revealing that these alterations can result
from multiple mechanisms even in a single genome
and that both DNA double-strand breaks and replica-
tion errors drive somatic rearrangements.INTRODUCTION
Cancer is a disease driven by genetic alterations, which include
single nucleotide variations (SNVs), structural variations (SVs),
and aneuploidy. The spectrum of somatic SNVs studied sug-gests that mismatch repair deficiency and specific mutagenic
exposure such as smoking, UV light, and chemotherapy can
be inferred from the mutational signatures for specific tumor
types (Greenman et al., 2007; Lee et al., 2010; Pleasance
et al., 2010a, 2010b). Larger scale SVs including deletions, inser-
tions, inversions, tandem duplications, translocations, and more
complex rearrangements constitute another frequent type of
alterations that could alter normal gene function in tumors.
Somatic SVs have been characterized in several previous
studies (Bass et al., 2011; Berger et al., 2011; Campbell et al.,
2010; Hillmer et al., 2011; Stephens et al., 2009); however, which
driving forces exist for SV formation is still unclear.
Three main types of mechanisms known to cause SVs are
homologous recombination, nonreplicative nonhomologous
repair, and replication-basedmechanisms (Gu et al., 2008; Hast-
ings et al., 2009b). Homologous recombination is the most com-
mon DNA repair mechanism and is generally accurate, except
when the pairing is between incorrect homologous regions, as
in nonallelic homologous recombination (NAHR). Deficiency in
homologous recombination is believed to be a major source of
cancer genome instability (Hoeijmakers, 2001). For example,
BRCA1 and BRCA2 are required for the homology-directed
repair of chromosomal breaks, and loss of these two genes often
results in genome instability and cancer (Venkitaraman, 2002).
Nonhomologous end joining (NHEJ) is a nonreplicative nonho-
mologous repair mechanism that requires no homology and
sometimes can generate very short microhomology or small
insertions at the breakpoint (Mahaney et al., 2009). In addition,
alternative end joining (alt-EJ) mechanism, also called microho-
mology-mediated end joining (MMEJ), can generate blunt ends,
small insertions, and, more frequently, microhomology at the
deletion breakpoints (Bennardo et al., 2008; McVey and Lee,
2008). Which factors are involved in alt-EJ is much less clear
than it is for NHEJ, and alt-EJ appears to be independent ofCell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc. 919
the canonical NHEJ factors such as Ku70 and XRCC4 (Arlt et al.,
2012; Bennardo et al., 2008). NHEJ has often been implicated in
tumor genomes, based on the very few overlapping sequences
at breakpoints (Stephens et al., 2009, 2011). For complex rear-
rangements, a replicative mechanism called fork stalling and
template switching (FoSTeS) has been described (Lee et al.,
2007), which later was generalized to microhomology-mediated
break-induced repair (MMBIR). It has been proposed that the
replication at the fork can stall and the polymerase can shift tem-
plate via microhomology to any nearby single-stranded DNA, re-
sulting in inversion, tandem duplication, translocation, or more
complex rearrangements (Hastings et al., 2009a; Zhang et al.,
2009). A recent assessment of SV formation (mostly focusing
on deletions) in a normal human population by the 1000
Genomes Project (Mills et al., 2011) did not address the role of
replication-based mechanisms. In cancer, a recent study
hypothesized that complex genomic rearrangements can arise
from a single catastrophic event (Stephens et al., 2011) driven
by NHEJ; similar complex rearrangements have also been
observed in pathogenic germline alterations (Chiang et al.,
2012). Another study suggested that multiple amplifications in
developmental delay and cognitive anomalous patients are
generated by a replication-based mechanism (Liu et al., 2011)
because microhomology is frequently observed at the break-
points. However, there is no comprehensive study of the
mechanisms that underlie somatic SVs in cancer genomes,
and many aspects are still poorly characterized, including the
forces that drive SV formation, relative contribution of different
mechanisms across tumor types, and whether additional mech-
anisms play a role.
In our analysis of somatic SVs across ten tumor types, non-
homology-based and microhomology-based mechanisms are
consistently the dominant mutational mechanisms responsible
for genomic rearrangements, driven by DNA double-strand
breaks and replication errors. Importantly, multiple mechanisms
sometimes act on a single gene in a genome, and two driving
forces can act together on a different part of a genome to create
mutations and promote tumorigenesis.
RESULTS
Identification of Germline Complex Deletion Events
Using Meerkat
To characterize the mutational spectrum of somatic SVs in can-
cer, it is important to identify both simple (e.g., deletion, inser-
tion, and inversion) and complex SVs at base-pair resolution.
Themost common type of complex SV is a deletionwith an inser-
tion or inversion at the breakpoint (Conrad et al., 2010; Kidd
et al., 2010) generated by FoSTeS/MMBIR. Previously, the iden-
tification of such events involved capturing and sequencing of
the segments adjacent to the deletion breakpoints (Conrad
et al., 2010; Kidd et al., 2010). Here, we predict both germline
and somatic SVs directly from short read data, focusing on com-
plex events such as those generated by FoSTeS/MMBIR (an
example shown in Figures 1A–1D). This is made possible by a
new algorithm called Meerkat (see Experimental Procedures;
see also the Extended Experimental Procedures available on-
line). With the base-pair resolution of the breakpoints identified920 Cell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc.by our method, the mechanisms forming SVs are inferred based
on sequence homology at the breakpoints (Kidd et al., 2010; Lam
et al., 2010; Mills et al., 2011) (Figure 1E; see also Discussion).
Identification of somatic SVs from short read data is challenging
due to several factors, including sequencing errors, GC content,
and other biases in sequencing, ambiguous alignments due to
repetitive sequences, a large number of germline SVs, chimeric
molecules generated during library construction, normal cell
contamination in tumor samples, and heterogeneity within tumor
cell populations. The distinguishing feature of our method is
that it considers the configuration of multiple clusters of discor-
dant read pairs (read pairs in which the mapped reads are at
unexpected distance or orientation) to recognize complex
events with high accuracy, in addition to efficiently utilizing split,
clipped, and multiple-aligned reads (Extended Experimental
Procedures).
To verify the accuracy of our method, we applied Meerkat
to two HapMap genomes (NA18507 and NA12878) that have
been sequenced at high coverage on the Illumina platform
and for which complex deletions have been previously reported
(Kidd et al., 2010) based on the sequencing of fosmid library
with 40 kb inserts. We identified a total of 3,508 and 2,327
SVs, respectively (Table S1). Of our simple deletion predictions
from NA18507 and NA12878, 91.4% (2,102/2,301) and 93.7%
(1,304/1,391) were reported in the Database of Genomic
Variants (DGV10) (Iafrate et al., 2004) or the 1000 Genomes
Project (Mills et al., 2011), respectively, suggesting that the
vast majority of our predictions were true events (Figure S1).
To further validate the events we detected, we randomly
selected 49 events across different types in NA18507 including
24 complex deletion events. We were able to validate 48 events
by PCR, including all complex deletions (Table S1). We identi-
fied a total of 379 and 253 complex deletions in NA18507 and
NA12878, demonstrating that our method is far more sensitive
than the previous effort, which reported 2 and 17 complex
deletions, respectively (Kidd et al., 2010). Therefore, with the
Meerkat algorithm, we can provide a more comprehensive
spectrum of mechanisms of SVs in a genome. An example
for a complex deletion in NA18507 identified by Meerkat is
shown in Figures 1A–1D (the same event was reported by
Kidd et al. (2010) but in a different individual NA18956).
Comparing our predictions to the simple and complex deletions
reported in Kidd et al. (2010), most of the events we failed to
identify occur in repetitive regions of the genome (Figure S1;
Table S2). This is expected because events reported by Kidd
et al. (2010) were based on Sanger sequencing. The examina-
tion of repetitive elements with short reads is a challenging
problem that we have addressed in a separate study (Lee
et al., 2012).
Somatic Structural Variations across Tumor Types
We analyzed high-coverage whole-genome sequencing data
from 140 individuals across ten tumor types, including 14 colo-
rectal adenocarcinoma (CRC) (Bass et al., 2011; Lee et al.,
2012), seven multiple myeloma (MM) (Chapman et al., 2011),
seven prostate adenocarcinoma (PR) (Berger et al., 2011), nine
ovarian serous cystadenocarcinoma (OV) (Lee et al., 2012),





Figure 1. Example of a Complex Deletion
Generated by FoSTeS/MMBIR and a Pipeline
for Predicting SV Mechanisms
(A) A complex deletion is predicted by three
discordant clusters. The sequence in light blue on
the reference is deleted; the sequence in red on the
reference is duplicated and inserted into the dele-
tion breakpoints. Three read pairs from the donor
are shown above the donor sequence. Three
discordant read pairs mapped to the reference are
shown above the reference sequence.
(B) Reads covering the breakpoints of insertion.
The breakpoints are covered by 27 and 11 reads,
respectively (only four are shown for each). Reads
matching different parts of the reference genome
are shown in the corresponding colors.
(C) Nucleotide sequences of the reads covering the
breakpoints of insertion. Black and red colors
indicate the reads and the reference sequences
that match each other and the gray sequences
indicate unmatched references. There are a 2 bp
microhomology (shown in purple) at the breakpoint
on the left and a 9 bp insertion of unknown
source (shown in dark green) at the breakpoint
on the right.
(D) Sequencing depth. Blue and red lines denote
the predicted deletion and the predicted insertion
donor sites, respectively, showing that the copy
number is consistent with the SV call.
(E) This flowchart shows the breakpoint features
for determining the mechanism that is likely to
have generated the observed SV. The classifica-
tion criteria are mainly adapted from Kidd et al.
(2010). Six types of mechanisms are assigned:
transposable element insertion (TEI), variable
number of tandem repeats (VNTR), nonhomolo-
gous end joining (NHEJ), alternative end joining
(alt-EJ), nonallelic homologous recombination
(NAHR), and fork stalling and template switching/
microhomology-mediated break induced repair
(FoSTeS/MMBIR).
See also Figure S1 and Tables S1 and S2.hepatocellular carcinoma (HCC) (Sung et al., 2012), 35 breast
invasive carcinoma (BRCA) (Cancer Genome Atlas Research
Network, 2012a), 19 lung squamous cell carcinoma (LUSC)
(Cancer Genome Atlas Research Network, 2012b), ten uterine
corpus endometrioid carcinoma (UCEC), and four kidney renal
clear cell carcinoma (KIRC) patients. With data from both tumor
and germline samples for each patient to distinguish germline
and somatic variants, a total of 140 pairs of genomes consisting
of about half trillion (458 billion, 353 coverage per genome on
average) paired-end reads (75–101 bp) were analyzed.
A total of 25,874 high-confidence somatic SVs (Table S3) were
identified from the 140 cancer genomes (Table S4), ranging from
0 to 3,160 per genome with an average of 185 (Figure 2A). To
assess the accuracy of somatic SV predictions, we randomly
selected 78 out of 138 SVs in an ovarian tumor (OV0725),
including two complex events with two breakpoints each, and
examined them in both tumor and normal tissues. By PCR, we
were able to validate 73 out of 80 (91%) breakpoints (Table S3)
as somatic events.The frequency of different types of somatic SVs in each
sample is shown in Figure 2A. We first note the remarkable vari-
ation in the number of SVs among individuals within and across
tumor types (the x axis for each tumor type is scaled differently in
Figure 2A). Some genomes contain no SV (e.g., LUSC1078 and
KIRC4856), whereas others show thousands of SVs (e.g.,
BRCAA0J6); in a single tumor type, the number of SVs can
vary by an order of magnitude between individuals. Among the
tumor types, breast tumors and lung squamous cell tumors
have significantly more SVs than any other tumors (p = 4.70e-
23 and 6.68e-5, respectively, ANOVA tests using a negative
binomial model). The number of SVs identified in breast cancer
patients here (16,125 in 35 patients, 461 per patient on
average) is much larger than those in previous studies (2,166 in
24 patients, 90 per patient on average (Stephens et al., 2009)
and 2,476 in 22 patients, 113 per patient on average (Banerji
et al., 2012), due to increased sequencing coverage, sensitivity
in the detection method, and sample variation. Kidney cancer
patients have significantly less SVs than other tumor typesCell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc. 921
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Figure 2. Spectrum of Somatic SV Types and Mechanisms
(A) Frequencies of types of somatic SVs identified in each patient. Each horizontal bar displays the number of SVs for one sample. The colored bar charts on the
left show the number of events scaled by the maximum number of events (as noted) in each tumor type. The black bar charts on the right show the number of
events for all patients on the same scale. A HapMap genome (NA18507) is shown at the top as an example of germline events; see Figure S2 for germline events
for all patients. Most (59%) of the translocations in NA18507 are TE insertions, as described previously (Lee et al., 2012), 18% are repeat-related events including
TE insertions not identified by Lee et al. (2012), and the remaining ones might be events too complex to be identified by Meerkat.
(B) Frequencies of somatic deletion mechanisms. The order of the samples is the same as in (A).
(C) Frequencies of somatic translocation mechanisms. The order of the samples is the same as in (A).
See also Figure S2 and Tables S3, S4, and S5.(p = 1.74e-5, ANOVA test using a negative binomial model).
In terms of event types, translocations (57%) are the most abun-
dant SV type, whereas deletions and tandem duplications make922 Cell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc.up 25% and 17%, respectively. The proportions of different
types of SVs across different tumor types are highly variable (Fig-
ure 2A). For instance, the breast tumors have significantly more
intrachromosomal translocations than other tumors types do
(p = 1.22e-53, ANOVA test using a negative binomial model).
There are also considerable differences between individual
genomes. For example, all rearrangements in a kidney sample
(KIRC5010) are deletions, whereas there are no deletions in a
liver cancer (HCC13). In nontumor samples, each individual
has about 3,000 germline SVs with deletions always being the
most abundant (60%) (Figure S2A), similar to what we find in
the HapMap individual NA18507 (Figure 2A).
By pairing multiple clusters of discordant reads to predict
complex events, we achieved a better description of the nature
of SVs than previously obtained. For example, in the PR0581
genome, a ‘‘close chain’’ pattern had been described to form
the TMPRSS2-ERG fusion gene, involving C21orf45 (Berger
et al., 2011). We identified two related events in this genome.
The first event is a 3 Mb deletion that causes the TMPRSS2-
ERG fusion. The second event is a 74 bp deletion in the first
intron of C21orf45 at which the 3 Mb deletion from the first
event was inserted. The copy numbers of the aforementioned
regions were unchanged, supporting the two events we pre-
dicted. Detailed descriptions of the events involving CDKN2A/B,
EGFR, and CDK4 are provided later.
Certain pathways, such as DNA replication, DNA repair, and
cell-cycle pathways, are likely to malfunction in order for the
cell to generate and maintain the genomic rearrangements. To
investigate this, we identified mutations in genes that in above
pathways caused by SVs as well as single nucleotide variants
(Bass et al., 2011; Berger et al., 2011; Chapman et al., 2011;
Cancer Genome Atlas Research Network, 2012a, 2012b). As ex-
pected, almost all patients have at least one gene altered in at
least one of these pathways (Table S5); nearly half of the muta-
tions are caused by SVs.
Mutational Mechanisms for Somatic SVs
The number of deletions per genome ranges from 0 to 395, with
an average of 46 (Figure 2B). Deletions are usually a result of
DNA double-strand break repair. The mechanisms of deletion
formation are predicted as shown in Figure 1E (see the Figure 1E
legend for information on how mechanistic categories were as-
signed). In the cancer genomes we studied, NHEJ (39%) and
alt-EJ (41%) are the dominant mechanisms. This is in contrast
to the mechanisms in the HapMap genome NA18507 (Figure 2B)
and nontumor genomes (Figure S2B), in which transposable
element insertion (TEI) is always the dominant mechanism, and
the frequencies of NHEJ and alt-EJ in germline deletions are
15% and 22%, respectively. The increased ratio of NHEJ to
alt-EJ in somatic deletions compared to that in germline is statis-
tically significant (p = 1.41e-12,Wilcoxon’s paired rank sum test).
We also find that about 20% of the somatic deletions are com-
plex deletions formed by FoSTeS/MMBIR (Figure 2B), in contrast
to 5% for the germline deletions (Figures 2B and S2B). The
mechanisms of somatic deletions are also variable across dif-
ferent tumor types and between samples. For instance, some
genomes have a notable portion of FoSTeS/MMBIR in somatic
deletions, whereas others have none (Figure 2B).
We identified between 0 and 2,999 inter- and intrachromoso-
mal translocations in the cancer genomeswith an average of 106
translocations per genome (Figure 2C). Again, NHEJ and alt-EJare the dominant mechanisms with alt-EJ being more abundant
in most cases. A small number of translocations are formed
by FoSTeS/MMBIR with variable frequencies across genomes.
Breast cancer patients have significantly more translocations
formed by alt-EJ than other tumor types (p = 4.21e-19, ANOVA
test using a negative binomial model). We note that the propor-
tion of translocations formed by NHEJ and alt-EJ are compara-
ble in most tumor types, but alt-EJ is much more prominent in
breast tumors that have a large number of translocations
(>500). The reason for this difference in translocation formation
in those samples is not clear, but it may be due to an alteration
in a specific pathway that induces translocations.
Tandem duplications are known to result from unequal
crossing over (Edlund andNormark, 1981) or by FoSTeS/MMBIR
(Hastings et al., 2009a). Short sequence homologies are required
for FoSTeS/MMBIR—the microhomology can be as short as
2 bp to allow new DNA synthesis to start (Zhang et al., 2009)—
whereas a larger degree of homology is required for unequal
crossing over. Complex rearrangements, especially ones in-
volving dosage gains, are often driven by FoSTeS/MMBIR
(Hastings et al., 2009a; Liu et al., 2011) as evidenced by the
microhomology frequently observed at the breakpoints. Events
with nomore than 10 bp insertions at breakpoints were classified
as NHEJ because NHEJ is known to generate small insertions at
breakpoints (Haviv-Chesner et al., 2007). In HapMap (Figure 3)
and other nontumor samples (Figures S3A and S3B), themajority
of the breakpoints of tandem duplications (73%) and complex
deletions (71%) have microhomology that support the MMBIR
models. In contrast, the fraction of breakpoints withmicrohomol-
ogy is significantly less in somatic tandem duplications (46%)
and complex deletions (52%) (p = 6.78e-19 and p = 1.09e-13,
respectively, using Wilcoxon’s paired rank sum test; Figures 3,
S3C, and S3D). Although most of the germline tandem duplica-
tions and complex deletions were generated by FoSTeS/MMBIR
(Figures S3A and S3C), a small number have no homology at the
breakpoints. In somatic tandem duplications and complex dele-
tions, we do not observe homology at many breakpoints (Fig-
ure 3). Thus, we suspect that a template-switching mechanism
that does not require microhomology or another non-homol-
ogy-based mechanism is often utilized in somatic cells to form
tandem duplications and complex deletions.
Reconstruction of Complex Rearrangements in GBM
Patients
We are particularly interested in GBM genomes because several
recurrent copy number alterationswe found are known to play an
important role in tumorigenesis (Cancer Genome Atlas Research
Network, 2008). In our 16 GBM whole-genome data sets, 15
genomes have loss of heterozygosity of chromosome 10, 12
have homozygous deletions of CDKN2A/B, 14 have EGFR
amplifications, and five have CDK4 amplifications (Table 1; see
also Extended Experimental Procedures; Figure S4). We tested
26 SVs involving loss or gain of CDKN2A/B, EGFR, and CDK4
and validated 25 as somatic SVs by PCR (Table S3).
Although the copy number changes in these regions have
been documented previously based on array data, the exact
configuration of the rearrangements and themechanisms under-
lying those events are largely unknown. Using Meerkat, we notCell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc. 923
Figure 3. Proportion of Homologies at the
Breakpoints of Somatic Tandem Duplica-
tions and Complex Deletions Compared
with NA18507
Homologies in base pairs are shown for each
breakpoint as a positive number. A blunt end has a
homology of 0 bp. Small insertions with unknown
source are shown as negative numbers. Somatic
tandem duplications and complex tandem dupli-
cations that are responsible for EGFR and CDK4
amplifications in GBM patients are shown in a
separate category.
See also Figure S3.only ascertained the types of events that generated the observed
configuration, but also gained insights into the mechanisms by
analyzing sequence homology at the breakpoints. It is interesting
to note that in both CDKN2A/B loss and EGFR gain, most tumor
genomes have both arm-level and focal loss/gain (Table 1). Out
of 12 patients harboring CDKN2A/B loss, six have arm-level loss
and focal deletions (Figure 4A), two have two independent focal
deletions (Figure 4B), and four have complex rearrangements
(Figure 4C). SVs responsible forCDKN2A/B loss in other patients
are displayed in Figure S5. Most (11 of 13) of the focal deletions
were generated by NHEJ, which suggests these alterations are
mostly formed through erroneous repair of DNA double-strand
breaks.
In the 14 GBM genomes with EGFR amplification, most have
more than one event contributing to the copy gain: nine with a
chromosome arm gain, eight with tandem duplication(s), one
with a complex tandem duplication, and eight with complex
events. For GBM0155 (Figure 5A), three tandem duplications
(1.6 Mb, 983 kb, and 28 kb) involving EGFR were identified. In
GBM0145 (Figure 5B), EGFR is amplified by a 789 kb tandem
duplication, but a complex deletion was also found (deletion of
a 417 kb fragment with insertion of a 50 kb fragment in the break-
point). From the copy ratios, it appears that this deletion only
affects a subset of the tandem-duplicated copies, suggesting
that it happened during the tandem duplication. The complex
deletion may not have been generated by FoSTeS/MMBIR
because no microhomology was found at the breakpoints. Simi-
larly, GBM0214 (Figure 5C) contains a 59 kb tandem duplication
and multiple subsequent rearrangements of various types in the
EGFR region that are exceedingly difficult to disentangle. SVs
responsible for EGFR amplifications in other patients are dis-
played in Figure S6.
In GBM0152, a 923 kb fragment covering EGFR (Figure 6A) is
merged with two fragments from chromosome 12 (a 5,620 bp
fragment and a 286 bp fragment in inverted orientation) and
then tandem-duplicated (Figure 6B). Moreover, nearly 40 regions
on chromosome 12 (including CDK4) are coalesced in an elabo-
rate complex series of events with the copy ratios of various
fragments at approximately 40-fold, 75-fold, and 110-fold gain924 Cell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc.(Figure 6C). In this case, the three promi-
nent copy ratios and all the amplified seg-
ments being connected by discordant
read pair clusters make it possible to
disentangle the underlying events (Fig-ure 6D). Based on the pattern of segments connected by discor-
dant read pairs and the corresponding copy ratio for each
segment (Figure 6E), we present one possible coamplified unit
(Figure 6F) that is consistent with all the observed copy ratios
and discordant read pairs, whereas other compatible configura-
tions are also possible. This single unit (Figure 6F), composed of
dozens of fragments, was tandem-duplicated to reach a copy
ratio of about 40.
While the complexity of the rearrangements in Figure 6C
is reminiscent of chromothripsis (Stephens et al., 2011), it is
unlikely to be the case here; instead, it is likely to have
been generated by a replication-based mechanism. Chromo-
somes that have undergone chromothripsis have copy
numbers that oscillate between two levels. The complex tan-
dem duplications in our example have several distinct copy
numbers, indicating that they are more likely to be a result of
a series of replication-based template-switching events. A
single unit of amplification contains multiple instances of the
segment (junctions 2–4, 12–14, 14–20, and 18–29 in Figure 6F);
it is unlikely that at least two copies of chromosome 12 were
shattered at the same place and joined with the same seg-
ments at the exact breakpoints after a ‘‘one-off’’ catastrophic
event. Therefore, we suspect that certain junctions (such as
14–20 in Figure 6F) were formed first by a template switching
event, and then the resulting fragment served as an additional
template in subsequent switching events to form more rear-
ranged fragments.
Most of the GBM patients examined in this study have both
EGFR gain, most likely through a replication-based mechanism,
and CDKN2A/B loss, mostly by NHEJ repair of DNA double-
strand breaks. Furthermore, in all tumor types, a significant
portion of the focal deletions was generated by FoSTeS/MMBIR
in addition to the dominant NHEJ and alt-EJ mechanisms. This
suggests that cancer genomes are likely to have more than
one driving force (e.g., replication error and erroneous repair of
DNA double-strand breaks) acting together in the same individ-
ual to initiate different types of rearrangements in different parts
of the genome and provide advantageous mutations for cancer
progression.
Table 1. CDKN2A/B Loss, Chromosome 10 Loss, and EGFR, CDK4 Amplification in GBM Samples
ID











RatioNHEJ alt-EJ AG Del Del_ins Dup CDup CP AG CDup CP
GBM0145 1 1 1 1 1 1 bi 66.9 1 mono 6.0
GBM0185 1 1 1 1 1 bi 24.8 1.0
GBM0188 1 1 1 mono 1.3 1.2
GBM0208 1 1 1 1 mono 19.1 1.1
GBM0214 1 1 1 1 1 mono 8.9 1 mono 1.5c
GBM0152 1 mono 61.8 1 mono 38.8
GBM0155 1 1 1 3 bi 5.7 0.9
GBM0648 1 1 1 mono 1.5c 1.2
GBM0786 1 1 1 1 bi 70.0 1.1
GBM0877 1 1 1 1 mono 17.9 1 mono 1.3
GBM0881a 1 mono 4.2 1.0
GBM1086 2 1.2 1.3
GBM1401 1b 1 1 bi 25.5 1.5c
GBM1438 1 bi 1.4 1 mono 11.6
GBM1454 1.1c 0.8
GBM1459 1 1 1 1 1 mono 33.3 0.8
The top five samples are the ones in which experimental validation ofCDKN2A/B loss, EGFR andCDK4 amplifications has been performed. Copy loss/
gain were predicted jointly from copy ratios and allele ratios of germline heterozygous SNPs. AL, arm-level loss; Del, deletion; Del_ins, deletion with
insertion in the breakpoints; CP, complex events; AG, arm-level gain; Dup, tandemduplication, CDup, complex tandemduplication. See also Extended
Experimental Procedures and Figure S4.
aThe only sample without chromosome 10 loss.
bDeletion that is also involved in a copy-neutral loss of heterozygosity event which caused the loss of both copies of CDKN2A/B.
cInconsistent copy ratio estimates between the read-depth and Affymetrix SNP Array 6.0 (http://tcga-data.nci.nih.gov/tcga/) data.Double Minute Chromosomes and Complex
Rearrangements
Double minute chromosomes (DMs) are extra circular chromo-
somal DNA with neither centromeres nor telomeres that can
duplicate autonomously. They have been found in a variety of
solid tumors as well as in leukemia (Thomas et al., 2004).
EGFR has been shown to be amplified by DMs in glioma and
glioblastoma (Vogt et al., 2004). All of the EGFR amplifications
we identified above are likely to be DMs because the amplified
fragments in DM loop structures would be predicted as tandem
duplications. With paired-end sequencing, we are not able to
determine if the amplifications were tandem duplications on
the same chromosome or circularized as doubleminute chromo-
somes. In one patient, we identified a deletion whose break-
points matched the tandem duplication (Figure S6G), suggesting
an excision of the DNA fragment followed by circularization of
that fragment, similar to the excisions of amplified DM fragments
reported based on FISH (Storlazzi et al., 2010; Van Roy et al.,
2006).
It was previously shown that most DMs that amplified EGFR in
gliomas are a single fragment circularized by a microhomology-
based mechanism (Vogt et al., 2004), likely FoSTeS/MMBIR
(microhomology was detected at six out of seven breakpoints),
and subsequently amplified by recombination to join multiple
fragments into one larger circular DNA or by rolling circle replica-
tion. The copy number of the amplified region we observed is the
average acrossmany tumor cells; each cell or a subpopulation ofcells could have a different number of the amplified unit. Most of
the initial circularizations of DMs in neuroblastoma and small cell
lung carcinoma (Storlazzi et al., 2010) were also generated by
FoSTeS/MMBIR, with 23 out of 32 breakpoints showing either
microhomologies or large insertions. Similar to EGFR amplifica-
tions in glioma, most of the EGFR and CDK4 amplifications in
GBM patients reported here can be explained by an initial circu-
larization of a single DNA fragment resulting from replication
error; others can be explained by the circularization of multiple
DNA fragments. However, we observed more breakpoints
without homology than with microhomology (Figure 3), suggest-
ing that some of these initial circularizations were generated by
FoSTeS/MMBIR butmore were formed by non-homology-based
replicative mechanisms.
DISCUSSION
We have reported a comprehensive catalog of somatic rear-
rangements in cancer, revealing the diversity in the types of
somatic SVs and the mechanisms that generate them across
different tumor types and individuals. Given the disruptive nature
of some genomic rearrangements and their role in promoting
cancer progression, precise characterization of the rearrange-
ments and their mechanisms is crucial. While much of the work
on structural variations so far has focused on their impact on
genes and the mutations occurring in intergenic regions have
often been considered ‘‘passenger’’ events, recent work by theCell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc. 925
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Figure 4. CDKN2A/B Losses in GBM Patients
(A–C) Profiles in the lower part of the plots show copy ratios (tumor versus
matched normal). Above the copy ratio profiles, predicted somatic SVs are
represented by lines with the breakpoints indicated by dots. SVs corre-
sponding to a notable copy number change are colored, with the color indi-
cating the orientation of the breakpoints. A red cluster typically suggests a
tandem duplication; a blue cluster typically suggests a deletion. The number of
supporting discordant read pairs for each SV is shown on the left using the
same color coding. The copy-loss regions are highlighted with blue shades.
(A) GBM0208, an arm-level loss and a focal deletion.
(B) GBM1086, two focal deletions.
(C) GBM0648, complex rearrangements.




Figure 5. EGFR Amplifications in GBM Patients
(A–C) SVs and copy ratios are displayed as described in Figure 4. The copy-
loss and gain regions are highlighted with blue and red shades, respectively.
(A) GBM0155, three tandem duplications.
(B) GBM0145, one tandem duplication and a deletion with insertion at the
breakpoints. Two vertical black lines connecting two single events denote a
complex deletion, which was predicted by combining two discordant read pair
clusters. The solid blue and red lines represent segments that have been
deleted and duplicated. The dashed lines denote a region of no copy number
change.
(C) GBM0214, one tandem duplication and complex rearrangements.
See also Figure S6.ENCODE consortium (Dunham et al., 2012) has shown that the
fraction of the noncoding genome that plays a role in gene regu-
lation is much larger than previously thought. This suggests that,
in addition to a direct impact on protein structure (e.g., by fusion
transcripts), other, perhaps more subtle types of misregulations
may result from rearrangements that involve noncoding regions
(e.g., disruption of enhancer activity or binding of a noncoding
RNA). Thus, it is advantageous to know not simply whether a
genomic region is amplified or not but also where the amplified
segments are located. At some point in the future, improved
DNA sequencing technology will accommodate much longer
reads (on the order of kilobases or longer) to make reconstruc-
tion of structural alterations easier; in the meantime, innovative
approaches such as the one we report here are needed to
dissect the evolution of the cancer genome based on short-
read data.926 Cell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc.It is important to note that assigning mechanisms to events
based on sequence features at the breakpoints is an inexact pro-
cess. For instance, we found that NHEJ and alt-EJ contribute the
most to focal deletions and translocations. The events generated
by alt-EJ tend to have more microhomology than by NHEJ
(Bennardo et al., 2008; McVey and Lee, 2008), but there is no
consensus cutoff for distinguishing NHEJ and alt-EJ (Arlt et al.,
2012), as both mechanisms can generate rearrangements with
blunt ends, microhomology, or small insertions at the break-
points. In addition, events generated by FoSTeS/MMBIR
frequently have microhomology at the breakpoints. These ambi-
guities in the thresholds, however, are unlikely tomaterially affect
our comparisons of germline and somatic events or compari-
sons across tumor types because we apply the same criteria





Figure 6. Amplifications of EGFR and Chromosome 12 in GBM0152
(A) Copy ratio and rearrangements involving EGFR. Colored boxes with arrows denote the amplified regions and their orientations.
(B) Diagram of the resulting rearrangements. Three segments of DNA from chromosome 7 and chromosome 12 are merged into one and tandem-duplicated.
(C) Copy ratio and somatic rearrangements on chromosome 12. The three gray dashed lines in copy ratio panel (bottom of this figure) denote copy ratios of 40, 75,
and 110. The rearrangements marked by ‘‘a,’’ ‘‘b,’’ ‘‘c,’’ and ‘‘d’’ have approximately twice as many supporting discordant read pairs as other rearrangements.
These rearrangements are also marked in (D)–(F).
(D) The 14 Mb region of chromosome 12 shown in (C) was segmented according to copy ratios. Each segment was rescaled and assigned an identifier from
0 to 40. The rearrangement marked with a black arrow is not involved in the amplifications of other segments on chromosome 12, but is involved in the
amplification of EGFR on chromosome 7 as displayed in (A).
(E) Each segment in (D) is shown as a numbered node connected by arrows and lines. Black arrows connected by lines denote concordant connections. Ratios of
segments are denoted by the number of dots above the segment IDs inside each node. Nonamplified segments are not shown. The connection marked with ‘‘e’’
(also marked in F) is a germline deletion.
(F) This diagram shows one possible solution on how segments are connected. Segments with a white background are in an inverted orientation. Colored dashed
lines denote discordant connections, whereas black lines denote concordant connections.require at least 100 bp of homology (Liskay et al., 1987;Waldman
and Liskay, 1988); therefore, we could not identify these SVs
generate by NAHR based on the short (%100 bp) reads we have.
We found more microhomology-based mechanisms (alt-EJ
and FoSTeS/MMBIR) for germline SVs (e.g., deletions, tandemduplications and complex events) than for somatic SVs, sug-
gesting that those mechanisms may be suppressed in cancer
cells. It is also possible that DNA breakage and replication fork
stalling are more frequent in cancer cells, and a non-homol-
ogy-based mechanism is the easiest way to repair. A similarCell 153, 919–929, May 9, 2013 ª2013 Elsevier Inc. 927
trend was observed in pathogenic germline rearrangements
(Chiang et al., 2012), with less microhomology at the breakpoints
of pathogenic balanced translocations and inversions.
The driving forces behind large-scale genomic rearrange-
ments have been less well characterized than those for single
nucleotide alterations. In addition to the chromosome arm-level
alterations (induced, e.g., by mutations in genes that maintain
genome stability; Solomon et al., 2011), focal losses and gains
of CDKN2A/B and EGFR in GBM patients involved distinct
mechanisms acting together on the same locus in the same
genome. Why multiple mechanisms act on certain regions of
the genome repeatedly remains unclear. The rearrangements
we observe are a snapshot of the combined effect of bias in for-
mation and selection of the alternations in cancer genomes. It is
possible that specific regions are biased toward the formation of
genomic rearrangement, driven by their genomic and epigenetic
features as well as their regulatory function (De and Michor,
2011a, 2011b; Fudenberg et al., 2011). For example, the recruit-
ment of specific proteins induced by androgen can trigger DNA
double-strand breaks that result in TMPRSS2-ERG gene fusion
in prostate cancer (Haffner et al., 2010). It is also possible that
alterations occur randomly for the most part and the fitness of
the cell increases with certain alterations. Further studies are
needed to better understand the relationships between the
driving forces and their targets and how each step of the alter-
ation confers growth advantage to the selected clones.
EXPERIMENTAL PROCEDURES
Identification of SVs Using the Meerkat Algorithm
In short, we predict SVs based on discordant read pairs and refine the precise
breakpoints by looking for the reads that cover the SV breakpoint junctions.
Mutational mechanisms are predicted based on homology and sequencing
features at the breakpoints (Figure 1E), which is adapted from Kidd et al.
(2010). See Extended Experimental Procedures for more details. The Meerkat
package is available online at http://compbio.med.harvard.edu/Meerkat/.
Experimental Validation of SVs
A set of SVs predicted by Meerkat was validated by PCR. PCR primers were
designed using Primer3 (http://frodo.wi.mit.edu/primer3/) to amplify the pre-
dicted SV breakpoints. The primer pairs were designed to produce a product
under 10 kb for SVs ofNA18507 or about 200 bp long for somatic SVs predicted
in cancer samples. ForNA18507, PCRswere run on genomicDNA. For somatic
SVs, PCRs were run on whole-genome amplified DNA of both tumor and
matched normal samples to ensure that the somatic SVs were found only in tu-
mor but not in the matched normal sample. Whole-genome DNA amplification
wasperformedwithSigma/Rubicon’sWGAkit permanufacturer’s instructions.
ForNA18507, five to ten SVswere randomly selected fromeach event type and
an SV was considered validated if the predicted product across breakpoints
was detectable in genomic DNA. For deletions with a large insertion in the
breakpoints, large insertions, deletions with an inversion in the breakpoints,
three PCRs were performed. Two PCRs were aimed at amplifying across the
two breakpoints, and the third PCRwas targeted to amplify the entire insertion
or inversion event if the insertion or inversion was <10 kb. An event was consid-
ered validated if all three PCRs yielded products of expected sizes. If a PCR
validation was not successful, two more pairs of primers were attempted.
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